Browse the evidence

Obesogenic stimuli promote adipose tissue macrophages to recruit neutrophils from the bone marrow in mice.

Understanding neutrophil recruitment can inform strategies to manage inflammation in obesity.

Inhibiting neutrophil recruitment out of the bone marrow in obese mice or during weight loss reduces bone marrow myelopoiesis and adipose tissue inflammation.

Targeting neutrophil recruitment may help reduce inflammation during obesity management.

In humans with obesity, plasma neutrophil chemokines are increased and correlate with increased insulin resistance, but do not decrease with weight loss.

Monitoring neutrophil chemokines may provide insights into insulin resistance in obese patients.

Current dietary practices reflect thousands of years of an almost Darwinian process of natural selection.

Understanding the historical context of dietary practices can inform current dietary recommendations.

More basic and applied research is needed to identify food consumption trends.

Increased research efforts can lead to better dietary policies and health outcomes.

Nitro-oleic acid (NO2-OA) treatment improves glucose tolerance in high fat diet (HFD)-fed Nrf2fl/fl mice but does not improve glucose tolerance in adipocyte-specific Nrf2 knockout (ANKO) mice.

NO2-OA may be effective for improving glucose tolerance in certain populations but not in those lacking Nrf2 in adipocytes.

Adipocyte-specific deletion of Nrf2 negates the protective effects of nitro-oleic acid on glucose tolerance.

Understanding the role of Nrf2 in adipocytes can inform strategies for managing glucose tolerance in obesity.

Nitro-oleic acid treatment does not alter body weight in Nrf2fl/fl and ANKO mice on both high fat diet (HFD) and low-fat diet (LFD).

NO2-OA may not affect body weight, suggesting its effects are more focused on metabolic parameters rather than weight loss.

Obesity is defined as a body mass index of ≥30 kg/m² (≥27 kg/m² for those of Asian descent).

Practitioners should use these BMI thresholds for diagnosing obesity.

Section 1115 Demonstration Waivers are currently serving as a temporary funding mechanism for nutrition-related programs.

Understanding the temporary nature of current funding can inform program planning.

MetFlex to fat showed no correlation to MetFlex measured during the clamp.

Different methods may yield different insights into metabolic flexibility.

Approximately 83.0% of patients in both treatment groups receive TSH testing within a 1-year follow-up.

Practitioners should note that a high percentage of older adults on levothyroxine are monitored for TSH after initiating GLP-1 RAs.

TSH testing patterns did not differ between GLP-1 RAs and SGLT-2is.

Clinicians can expect similar TSH monitoring practices regardless of whether patients are on GLP-1 RAs or SGLT-2is.

The mean time to TSH testing was approximately 130.5 days for both groups.

Practitioners should be aware that TSH testing occurs on average about 130 days after treatment initiation.

Obesity has been associated with improved prognosis in patients with established cardiovascular diseases (CVD), particularly coronary heart disease (CHD), heart failure (HF), atrial fibrillation, and pulmonary arterial hypertension.

Clinicians should consider the potential for improved prognosis in obese patients with established CVD when making treatment decisions.

Viscosity seems to have no effect on active CCK and glucagon-like peptide-1.

Practitioners should note that the viscosity of chocolate does not affect CCK or GLP-1 levels.

Future research should standardize economic evaluation methods in SET studies for better comparison across diverse interventions, settings, and populations.

Researchers should aim for consistent evaluation methods to enhance the validity of findings in SET studies.

No significant findings emerged in White women, African American men, or for the 8-10 week outcomes regarding WCadjBMI or WHRadjBMI.

Results may not be generalizable to all demographic groups, indicating the need for tailored approaches in interventions.

Mean total costs per person-year decreased from $5227.25 to $4982.88 over three years.

Cost management strategies may be effective in obesity care over time.

Obesity has increased from 30.5% during 1999–2000 to 41.9% during 2017–2020.

Health practitioners should be aware of the rising obesity rates when designing interventions.

Diabetic nephropathy affects approximately 700 million people worldwide and is the leading cause of chronic kidney insufficiency.

Healthcare providers should be aware of the high prevalence of diabetic nephropathy in T2D patients.

There is significant societal attention on the issues of overweight and obesity.

Practitioners should be aware of the societal context when addressing obesity in patients.

There was no significant difference in the cost of diabetes therapy between the two groups (p = 0.12).

Practitioners can consider that an open formulary may improve glycemic control without increasing costs.

Effective nephroprotection requires early identification of at-risk patients through screening.

Implement routine screening for CKD risk factors in clinical practice.